BRCA2 and prostate carcinoma: BRCA2 deficiency is a well-established predictor for response to PARP inhibition, while concurrent APC mutation—leading to Wnt pathway activation—has been linked to resistance against androgen deprivation and to neuroendocrine differentiation in advanced prostate cancer (11, 36, 37).